Yahoo · Aug 13, 2026
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AN
NASDAQ · ANGO
AngioDynamics, Inc.
Healthcare · Medical - Instruments & Supplies
$15.27
Up+$0.03 (+0.20%)
Updated Sep 13, 2026, 2:16 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 471.53M
- P/E ratio
- -17.09
- Dividend yield
- 0.00%
- 52-week range
- $9.39 – $16.29
- Volume
- 341.96K
- Avg. volume
- 570.39K
Price performance
ANGO price history
1M range · 19 trading sessions · Daily adjusted prices
ANGO closed at $15.27 after 19 trading sessions, down 2.55% for the selected period.
- Last close
- $15.27
- Period change
- -2.55%
- Period low
- $15.20
- Period high
- $16.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $15.44 | $15.47 | $15.065 | $15.27 | 341.96K |
| Sep 10, 2026 | $15.21 | $15.46 | $15.01 | $15.24 | 238.75K |
| Sep 9, 2026 | $15.09 | $15.36 | $14.935 | $15.32 | 328.78K |
| Sep 8, 2026 | $15.08 | $15.39 | $15.02 | $15.22 | 432.09K |
| Sep 4, 2026 | $15.36 | $15.44 | $14.85 | $15.20 | 527.44K |
| Sep 3, 2026 | $15.78 | $15.83 | $15.16 | $15.47 | 438.28K |
| Sep 2, 2026 | $15.90 | $16.215 | $15.52 | $15.62 | 311.41K |
| Sep 1, 2026 | $16.16 | $16.29 | $15.78 | $15.86 | 237.94K |
| Aug 31, 2026 | $15.80 | $16.22 | $15.63 | $16.13 | 358.53K |
| Aug 28, 2026 | $15.88 | $15.97 | $15.68 | $15.85 | 200.74K |
| Aug 27, 2026 | $15.62 | $15.95 | $15.60 | $15.78 | 295.46K |
| Aug 26, 2026 | $15.87 | $15.96 | $15.54 | $15.69 | 242.4K |
| Aug 25, 2026 | $15.84 | $15.99 | $15.60 | $15.95 | 280.4K |
| Aug 24, 2026 | $15.73 | $15.79 | $15.535 | $15.77 | 179.11K |
| Aug 21, 2026 | $15.85 | $15.85 | $15.6001 | $15.75 | 150.07K |
| Aug 20, 2026 | $15.67 | $16.155 | $15.67 | $15.82 | 160.69K |
| Aug 19, 2026 | $16.06 | $16.29 | $15.8301 | $16.07 | 305.5K |
| Aug 18, 2026 | $15.68 | $16.05 | $15.475 | $15.82 | 335.66K |
| Aug 17, 2026 | $15.38 | $15.74 | $15.27 | $15.67 | 304.58K |
Latest ANGO news
The latest Smart Investors Daily articles mentioning ANGO.
Stock researchCompany · Overview
ANGO research
Overview
Company profile and research snapshot.
Company profile
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2026 | Canaccord Genuity | Buy | — |
| Apr 6, 2026 | Freedom Broker | Buy | — |
| Apr 6, 2026 | Canaccord Genuity | Buy | — |
| Oct 3, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock moved upwards by
SeekingAlpha · Aug 11, 2026
AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow
2026-08-11. The following slide deck was published by AngioDynamics, Inc.
Yahoo · Aug 6, 2026
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
